• 主题
高级搜索  >
历史搜索 清空历史
首页> 中文期刊> 《癌症（英文版）》 >Prognostic role of ABO blood type in patients with extranodal natural killer/T cell lymphoma, nasal type: a triple-center study

Prognostic role of ABO blood type in patients with extranodal natural killer/T cell lymphoma, nasal type: a triple-center study

         
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Background:The prognostic significance of ABO blood type for lymphoma is largely unknown.We evaluated the prognostic role of ABO blood type in patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTL).Methods:We retrospectively analyzed clinical data of 697 patients with newly diagnosed ENKTL from three cancer centers.The prognostic value of ABO blood type was evaluated using Kaplan-Meier curves and Cox proportional hazard models.The prognostic values of the International Prognostic Index (IPI) and the Korean Prognostic Index (KPI) were also evaluated.Results:Compared with patients with blood type O,those with blood type non-O tended to display elevated baseline serum C-reactive protein levels (P =0.038),lower rate of complete remission (P =0.005),shorter progression-free survival (PFS,P ＜ 0.001),and shorter overall survival (OS,P =0.001).Patients with blood type O/AB had longer PFS (P ＜ 0.001) and OS (P =0.001) compared with those with blood type A/B.Multivariate analysis demonstrated that age ＞60 years (P ＜ 0.001),mass ＞5 cm (P =0.001),stage Ⅲ/Ⅳ (P ＜ 0.001),elevated serum lactate dehydrogenase (LDH) levels (P =0.001),and blood type non-O were independent adverse predictors of OS (P =0.001).ABO blood type was found to be superior to both the IPI in discriminating patients with different outcomes in the IPI low-risk group and the KPI in distinguishing between the intermediate-to-low-and high-to-intermediate-risk groups.Conclusions:ABO blood type was an independent predictor of clinical outcome for patients with ENKTL.

著录项

  • 来源
    《癌症（英文版）》 |2017年第009期|427-437|共11页
  • 作者

    Ya-Jun Li; Ping-Yong Yi; Ji-Wei Li; Xian-Ling Liu; Tian Tang; Pei-Ying Zhang; Wen-Qi Jiang;

  • 作者单位

    Department of Lymphoma and Hematology, Hunan Cancer Hospital, 283 Tongzipo Road, Yuelu District, Changsha 410013, Hunan, P.R.China;

    The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, Hunan, P.R.China;

    Department of Lymphoma and Hematology, Hunan Cancer Hospital, 283 Tongzipo Road, Yuelu District, Changsha 410013, Hunan, P.R.China;

    The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, Hunan, P.R.China;

    Department of Lymphoma and Hematology, Hunan Cancer Hospital, 283 Tongzipo Road, Yuelu District, Changsha 410013, Hunan, P.R.China;

    The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, Hunan, P.R.China;

    Cancer Center of the Second Xiangya Hospital, Central South University, Changsha 410013, Hunan, P.R.China;

    The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, Hunan, P.R.China;

    Radioactive Interventional Department, Hunan Cancer Hospital, Changsha 410013, Hunan, P.R.China;

    Integration Medicine Department, Hunan Chest Hospital, Changsha, Hunan 410013, P.R.China;

    Department of Medical Oncology, Sun Yat-sen University Cancer Center;

    State Key Laboratory of Oncology in South China;

    Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng RD East, Guangdong 510060, Guangdong, P.R.China;

  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号